Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital

Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Long-term Follow-up From the Randomized SCHEDULE Study

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Cytomegalovirus Viral Load in Bronchoalveolar Lavage to Diagnose Lung Transplant Associated CMV Pneumonia

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Survival Benefit in Renal Transplantation Despite High Comorbidity

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Transplantation With Livers From Deceased Donors Older Than 75 Years

    Research output: Contribution to journalJournal articleResearchpeer-review

  • Finn Gustafsson
  • Arne K Andreassen
  • Bert Andersson
  • Hans Eiskjær
  • Göran Rådegran
  • Einar Gude
  • Kjell Jansson
  • Dag Solbu
  • Kristjan Karason
  • Satish Arora
  • Göran Dellgren
  • Lars Gullestad
  • SCHEDULE (Scandinavian Heart Transplant Everolimus De Novo Study With Early Calcineurin Inhibitors Avoidance) Investigators
View graph of relations

BACKGROUND: A calcineurin inhibitor (CNI)-free immunosuppressive regimen has been demonstrated to improve renal function early after heart transplantation, but long-term outcome of such a strategy has not been well described.

METHODS: In the randomized SCHEDULE trial, de novo heart transplant recipients received (1) everolimus with reduced-exposure CNI (cyclosporine) followed by CNI withdrawal at week 7-11 posttransplant or (2) standard-exposure cyclosporine, both with mycophenolate mofetil and corticosteroids; 95/115 randomized patients were followed up at 5-7 years posttransplant.

RESULTS: Mean measured glomerular filtration rate was 74.7 mL/min and 62.4 mL/min with everolimus and CNI, respectively. The mean difference was in favor of everolimus by 11.8 mL/min in the intent-to-treat population (P = 0.004) and 17.2 mL/min in the per protocol population (n = 75; P < 0.001). From transplantation to last follow-up, the incidence of biopsy-proven acute rejection (BPAR) was 77% (37/48) and 66% (31/47) (P = 0.23) with treated BPAR in 50% and 23% (P < 0.01) in the everolimus and CNI groups, respectively; no episode led to hemodynamic compromise. Coronary allograft vasculopathy (CAV) assessed by coronary intravascular ultrasound was present in 53% (19/36) and 74% (26/35) of everolimus- and CNI-treated patients, respectively (P = 0.037). Graft dimensions and function were similar between the groups. Late adverse events were comparable.

CONCLUSIONS: These results suggest that de novo heart transplant patients randomized to everolimus and low-dose CNI followed by CNI-free therapy maintain significantly better long-term renal function as well as significantly reduced CAV than patients randomized to standard CNI treatment. Increased BPAR in the everolimus group during year 1 did not impair long-term graft function.

Original languageEnglish
Issue number1
Pages (from-to)154-164
Number of pages11
Publication statusPublished - 1 Jan 2020

ID: 57664193